Jefferies Financial Group Inc. Has $593,000 Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)

Jefferies Financial Group Inc. cut its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 98.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,600 shares of the biopharmaceutical company's stock after selling 1,176,400 shares during the period. Jefferies Financial Group Inc.'s holdings in Cytokinetics were worth $593,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Inspire Investing LLC boosted its position in Cytokinetics by 7.8% during the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company's stock worth $400,000 after acquiring an additional 616 shares during the period. Blue Trust Inc. raised its stake in shares of Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 842 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Cytokinetics by 2.9% during the fourth quarter. Pacer Advisors Inc. now owns 24,843 shares of the biopharmaceutical company's stock valued at $1,169,000 after purchasing an additional 690 shares in the last quarter. R Squared Ltd acquired a new stake in Cytokinetics in the fourth quarter worth about $133,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Cytokinetics by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,023 shares of the biopharmaceutical company's stock valued at $1,177,000 after buying an additional 2,393 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have commented on CYTK shares. Cantor Fitzgerald upgraded shares of Cytokinetics to a "strong-buy" rating in a research report on Tuesday, May 13th. Bank of America lowered their price objective on shares of Cytokinetics from $62.00 to $54.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 15th. JMP Securities reissued a "market outperform" rating and set a $78.00 target price on shares of Cytokinetics in a report on Thursday, April 10th. Barclays cut their target price on Cytokinetics from $55.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, UBS Group lowered their price target on Cytokinetics from $47.00 to $41.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $74.44.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 2,775 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.38, for a total transaction of $123,154.50. Following the sale, the executive vice president now directly owns 34,888 shares of the company's stock, valued at $1,548,329.44. The trade was a 7.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Wendall Wierenga sold 20,000 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $38.46, for a total value of $769,200.00. Following the completion of the sale, the director now owns 24,848 shares of the company's stock, valued at $955,654.08. The trade was a 44.60% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 94,816 shares of company stock valued at $3,850,385. 2.70% of the stock is currently owned by corporate insiders.

Cytokinetics Price Performance

Shares of CYTK traded down $0.42 during trading hours on Thursday, hitting $30.89. 213,696 shares of the company were exchanged, compared to its average volume of 1,687,549. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The company has a market capitalization of $3.69 billion, a PE ratio of -5.74 and a beta of 0.81. The firm has a fifty day simple moving average of $38.12 and a 200-day simple moving average of $44.86. Cytokinetics, Incorporated has a one year low of $29.31 and a one year high of $61.38.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.77 million. The company's revenue for the quarter was up 89.1% compared to the same quarter last year. During the same quarter last year, the business earned ($1.33) EPS. As a group, sell-side analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.